Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 768, Issue C, 2014, Pages 22-34

  Kundu, Juthika ^a   Chun, Kyung Soo ^a   Aruoma, Okezie I ^b   Kundu, Joydeb Kumar ^a  

^a Keimyung University   (South Korea)

^b American University of Health Sciences   (United States)

Author keywords

Anti inflammatory effects of thymoquinone; Apoptosis and natural products; Cancer therapy and chemoprevention; Inflammation and cancer; Thymoquinione as antioxidant supplement; Thymoquinone from black cumin seeds

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; THYMOQUINONE;

ANIMAL; BLACK CUMIN; CELL TRANSFORMATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PLANT SEED; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZOQUINONES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NIGELLA SATIVA; SEEDS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929044434     PISSN: 00275107     EISSN: 18792871     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2014.05.003     Document Type: Review

References (123)

1. Mann J.R., Backlund M.G., DuBois R.N. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol. 2005, 2:202-210.
2. Baer-Dubowska W. Cancer chemopreventive agents-drugs for the 21st century?. Acta Pol. Pharm. 2006, 63:369-373.
3. Banerjee S., Wang Z., Mohammad M., Sarkar F.H., Mohammad R.M. Efficacy of selected natural products as therapeutic agents against cancer. J. Nat. Prod. 2008, 71:492-496.
4. Cassady J.M., Baird W.M., Chang C.J. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J. Nat. Prod. 1990, 53:23-41.
5. Choi J.S., Chun K.S., Kundu J., Kundu J.K. Biochemical basis of cancer chemoprevention and/or chemotherapy with ginsenosides. Int. J. Mol. Med. 2013, 32:1227-1238. (Review).
6. Wang H., Khor T.O., Shu L., Su Z.Y., Fuentes F., Lee J.H., Kong A.N. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med. Chem. 2012, 12:1281-1305.
7. Salomi M.J., Nair S.C., Panikkar K.R. Inhibitory effects of Nigella sativa and saffron (Crocus sativus) on chemical carcinogenesis in mice. Nutr. Cancer 1991, 16:67-72.
8. El-Dakhakhany M. Studies on the chemical constitution of Egyptian N. sativa L. seeds. Planta Med. 1963, 11:465-470.
9. Johnson H.A., Rogers L.L., Alkire M.L., McCloud T.G., McLaughlin J.L. Bioactive monoterpenes from Monarda fistulosa (Lamiaceae). Nat. Prod. Lett. 1998, 11:241-250.
10. Worthen D.R., Ghosheh O.A., Crooks P.A. The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res. 1998, 18:1527-1532.
11. Badary O.A., Al-Shabanah O.A., Nagi M.N., Al-Rikabi A.C., Elmazar M.M. Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur. J. Cancer Prev. 1999, 8:435-440.
12. Badary O.A., Gamal El-Din A.M. Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. Cancer Detect. Prev. 2001, 25:362-368.
13. Rajkamal G., Suresh K., Sugunadevi G., Vijayaanand M.A., Rajalingam K. Evaluation of chemopreventive effects of thymoquinone on cell surface glycoconjugates and cytokeratin expression during DMBA induced hamster buccal pouch carcinogenesis. BMB Rep. 2010, 43:664-669.
14. Jrah-Harzallah H., Ben-Hadj-Khalifa S., Almawi W.Y., Maaloul A., Houas Z., Mahjoub T. Effect of thymoquinone on 1,2-dimethyl-hydrazine-induced oxidative stress during initiation and promotion of colon carcinogenesis. Eur. J. Cancer 2013, 49:1127-1135.
15. Gali-Muhtasib H., Ocker M., Kuester D., Krueger S., El-Hajj Z., Diestel A., Evert M., El-Najjar N., Peters B., Jurjus A., Roessner A., Schneider-Stock R. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J. Cell. Mol. Med. 2008, 12:330-342.
16. Lang M., Borgmann M., Oberhuber G., Evstatiev R., Jimenez K., Dammann K.W., Jambrich M., Khare V., Campregher C., Ristl R., Gasche C. Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling. Mol. Cancer 2013, 12:41.
17. Connelly L., Barham W., Onishko H.M., Sherrill T., Chodosh L.A., Blackwell T.S., Yull F.E. Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene 2011, 30:1402-1412.
18. Raghunandhakumar S., Paramasivam A., Senthilraja S., Naveenkumar C., Asokkumar S., Binuclara J., Jagan S., Anandakumar P., Devaki T. Thymoquinone inhibits cell proliferation through regulation of G1/S phase cell cycle transition in N-nitrosodiethylamine-induced experimental rat hepatocellular carcinoma. Toxicol. Lett. 2013, 223:60-72.
19. Woo C.C., Hsu A., Kumar A.P., Sethi G., Tan K.H. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS ONE 2013, 8:e75356.
20. Lei X., Lv X., Liu M., Yang Z., Ji M., Guo X., Dong W. Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem. Biophys. Res. Commun. 2012, 417:864-868.
21. Ivankovic S., Stojkovic R., Jukic M., Milos M., Jurin M. The antitumor activity of thymoquinone and thymohydroquinone in vitro and in vivo. Exp. Oncol. 2006, 28:220-224.
22. Kaseb A.O., Chinnakannu K., Chen D., Sivanandam A., Tejwani S., Menon M., Dou Q.P., Reddy G.P. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007, 67:7782-7788.
23. Yi T., Cho S.G., Yi Z., Pang X., Rodriguez M., Wang Y., Sethi G., Aggarwal B.B., Liu M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther. 2008, 7:1789-1796.
24. Jafri S.H., Glass J., Shi R., Zhang S., Prince M., Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J. Exp. Clin. Cancer Res. 2010, 29:87.
25. Banerjee S., Padhye S., Azmi A., Wang Z., Philip P.A., Kucuk O., Sarkar F.H., Mohammad R.M. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr. Cancer 2010, 62:938-946.
26. Guengerich F.P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 1991, 4:391-407.
27. Elbarbry F., Ragheb A., Marfleet T., Shoker A. Modulation of hepatic drug metabolizing enzymes by dietary doses of thymoquinone in female New Zealand White rabbits. Phytother. Res. 2012, 26:1726-1730.
28. Gallagher E.P., Wienkers L.C., Stapleton P.L., Kunze K.L., Eaton D.L. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res. 1994, 54:101-108.
29. Nili-Ahmadabadi A., Tavakoli F., Hasanzadeh G., Rahimi H., Sabzevari O. Protective effect of pretreatment with thymoquinone against Aflatoxin B(1) induced liver toxicity in mice. DARU 2011, 19:282-287.
30. Motaghed M., Al-Hassan F.M., Hamid S.S. Thymoquinone regulates gene expression levels in the estrogen metabolic and interferon pathways in MCF7 breast cancer cells. Int. J. Mol. Med. 2014, 33:8-16.
31. Al-Dalaen S., Mahgoub S., Al-Qtaitat A. Carcinogen metabolizing enzymes: modulation of their activities in liver, lung and stomach by thymoquinone. Eur. J. Med. Plants 2014, 4:383-393.
32. Trafalis D.T., Panteli E.S., Grivas A., Tsigris C., Karamanakos P.N. CYP2E1 and risk of chemically mediated cancers. Expert Opin. Drug Metab. Toxicol. 2010, 6:307-319.
33. Aruoma O.I., Kaur H., Halliwell B. Oxygen free radicals and human diseases. J. R. Soc. Health 1991, 111:172-177.
34. Badary O.A., Taha R.A., Gamal el-Din A.M., Abdel-Wahab M.H. Thymoquinone is a potent superoxide anion scavenger. Drug Chem. Toxicol. 2003, 26:87-98.
35. Khan M.A., Anwar S., Aljarbou A.N., Al-Orainy M., Aldebasi Y.H., Islam S., Younus H. Protective effect of thymoquinone on glucose or methylglyoxal-induced glycation of superoxide dismutase. Int. J. Biol. Macromol. 2014, 65C:16-20.
36. Schneider-Stock R., Fakhoury I.H., Zaki A.M., El-Baba C.O., Gali-Muhtasib H.U. Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov. Today 2014, 19:18-30.
37. Khalife K.H., Lupidi G. Nonenzymatic reduction of thymoquinone in physiological conditions. Free Radic. Res. 2007, 41:153-161.
38. Surh Y.J., Kundu J.K., Na H.K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008, 74:1526-1539.
39. Nagi M.N., Almakki H.A. Thymoquinone supplementation induces quinone reductase and glutathione transferase in mice liver: possible role in protection against chemical carcinogenesis and toxicity. Phytother. Res. 2009, 23:1295-1298.
40. Sayed-Ahmed M.M., Aleisa A.M., Al-Rejaie S.S., Al-Yahya A.A., Al-Shabanah O.A., Hafez M.M., Nagi M.N. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid. Med. Cell Longev. 2010, 3:254-261.
41. El-Sayed W.M. Upregulation of chemoprotective enzymes and glutathione by Nigella sativa (black seed) and thymoquinone in CCl4-intoxicated rats. Int. J. Toxicol. 2011, 30:707-714.
42. Kundu J.K., Liu L., Shin J.W., Surh Y.J. Thymoquinone inhibits phorbol ester-induced activation of NF-kappaB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo. Biochem. Biophys. Res. Commun. 2013, 438:721-727.
43. Kundu J., Kim D.H., Kundu J.K., Chun K.S. Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKalpha as upstream targets. Food Chem. Toxicol. 2013, 65C:18-26.
44. Long D.J., Waikel R.L., Wang X.J., Perlaky L., Roop D.R., Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 2000, 60:5913-5915.
45. Long D.J., Waikel R.L., Wang X.J., Roop D.R., Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J. Natl. Cancer Inst. 2001, 93:1166-1170.
46. Was H., Sokolowska M., Sierpniowska A., Dominik P., Skrzypek K., Lackowska B., Pratnicki A., Grochot-Przeczek A., Taha H., Kotlinowski J., Kozakowska M., Mazan A., Nowak W., Muchova L., Vitek L., Ratajska A., Dulak J., Jozkowicz A. Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice. Free Radic. Biol. Med. 2011, 51:1717-1726.
47. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121:2373-2380.
48. Kundu J.K., Surh Y.J. Emerging avenues linking inflammation and cancer. Free Radic. Biol. Med. 2012, 52:2013-2037.
49. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
50. Kundu J.K., Surh Y.J. Inflammation: gearing the journey to cancer. Mutat. Res. 2008, 659:15-30.
51. Porta C., Larghi P., Rimoldi M., Totaro M.G., Allavena P., Mantovani A., Sica A. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 2009, 214:761-777.
52. Mahgoub A.A. Thymoquinone protects against experimental colitis in rats. Toxicol. Lett. 2003, 143:133-143.
53. Lei X., Liu M., Yang Z., Ji M., Guo X., Dong W. Thymoquinone prevents and ameliorates dextran sulfate sodium-induced colitis in mice. Dig. Dis. Sci. 2012, 57:2296-2303.
54. Juhas S., Cikos S., Czikkova S., Vesela J., Il'kova G., Hajek T., Domaracka K., Domaracky M., Bujnakova D., Rehak P., Koppel J. Effects of borneol and thymoquinone on TNBS-induced colitis in mice. Folia Biol. (Praha) 2008, 54:1-7.
55. El Gazzar M.A. Thymoquinone suppresses in vitro production of IL-5 and IL-13 by mast cells in response to lipopolysaccharide stimulation. Inflamm. Res. 2007, 56:345-351.
56. El Mezayen R., El Gazzar M., Nicolls M.R., Marecki J.C., Dreskin S.C., Nomiyama H. Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol. Lett. 2006, 106:72-81.
57. Fujisawa T., Joshi B.H., Puri R.K. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int. J. Cancer 2012, 131:344-356.
58. Lee E.J., Lee S.J., Kim S., Cho S.C., Choi Y.H., Kim W.J., Moon S.K. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-kappaB/AP-1 pathway: involvement of the p21WAF1 expression. Cell. Signal. 2013, 25:2025-2038.
59. El-Mahmoudy A., Matsuyama H., Borgan M.A., Shimizu Y., El-Sayed M.G., Minamoto N., Takewaki T. Thymoquinone suppresses expression of inducible nitric oxide synthase in rat macrophages. Int. Immunopharmacol. 2002, 2:1603-1611.
60. Marsik P., Kokoska L., Landa P., Nepovim A., Soudek P., Vanek T. In vitro inhibitory effects of thymol and quinones of Nigella sativa seeds on cyclooxygenase-1- and -2-catalyzed prostaglandin E2 biosyntheses. Planta Med. 2005, 71:739-742.
61. Attoub S., Sperandio O., Raza H., Arafat K., Al-Salam S., Al Sultan M.A., Al Safi M., Takahashi T., Adem A. Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam. Clin. Pharmacol. 2013, 27:557-569.
62. Na H.K., Park J.M., Lee H.G., Lee H.N., Myung S.J., Surh Y.J. 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem. Pharmacol. 2011, 82:1352-1360.
63. Rajput S., Kumar B.N., Dey K.K., Pal I., Parekh A., Mandal M. Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells. Life Sci. 2013, 93:783-790.
64. Shoieb A.M., Elgayyar M., Dudrick P.S., Bell J.L., Tithof P.K. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int. J. Oncol. 2003, 22:107-113.
65. Gali-Muhtasib H., Diab-Assaf M., Boltze C., Al-Hmaira J., Hartig R., Roessner A., Schneider-Stock R. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int. J. Oncol. 2004, 25:857-866.
66. Ashour A.E., Abd-Allah A.R., Korashy H.M., Attia S.M., Alzahrani A.Z., Saquib Q., Bakheet S.A., Abdel-Hamied H.E., Jamal S., Rishi A.K. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. Mol. Cell. Biochem. 2014.
67. Roepke M., Diestel A., Bajbouj K., Walluscheck D., Schonfeld P., Roessner A., Schneider-Stock R., Gali-Muhtasib H. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol. Ther. 2007, 6:160-169.
68. Gali-Muhtasib H.U., Abou Kheir W.G., Kheir L.A., Darwiche N., Crooks P.A. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs 2004, 15:389-399.
69. Motaghed M., Al-Hassan F.M., Hamid S.S. Cellular responses with thymoquinone treatment in human breast cancer cell line MCF-7. Pharmacognosy Res. 2013, 5:200-206.
70. Yin Z., Song Y., Rehse P.H. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem. Biol. 2013, 8:303-308.
71. Martin B.T., Strebhardt K. Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 2006, 5:2881-2885.
72. Garcia-Alvarez B., de Carcer G., Ibanez S., Bragado-Nilsson E., Montoya G. Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3107-3112.
73. Yun S.M., Moulaei T., Lim D., Bang J.K., Park J.E., Shenoy S.R., Liu F., Kang Y.H., Liao C., Soung N.K., Lee S., Yoon D.Y., Lim Y., Lee D.H., Otaka A., Appella E., McMahon J.B., Nicklaus M.C., Burke T.R., Yaffe M.B., Wlodawer A., Lee K.S. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat. Struct. Mol. Biol. 2009, 16:876-882.
74. Reindl W., Yuan J., Kramer A., Strebhardt K., Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem. Biol. 2008, 15:459-466.
75. Ng W.K., Yazan L.S., Ismail M. Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Toxicol. In Vitro 2011, 25:1392-1398.
76. Paramasivam A., Sambantham S., Shabnam J., Raghunandhakumar S., Anandan B., Rajiv R., Vijayashree Priyadharsini J., Jayaraman G. Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP. Toxicol. Lett. 2012, 213:151-159.
77. Dergarabetian E.M., Ghattass K.I., El-Sitt S.B., Al-Mismar R.M., El-Baba C.O., Itani W.S., Melhem N.M., El-Hajj H.A., Bazarbachi A.A., Schneider-Stock R., Gali-Muhtasib H.U. Thymoquinone induces apoptosis in malignant T-cells via generation of ROS. Front. Biosci. (Elite Ed.) 2013, 5:706-719.
78. Koka P.S., Mondal D., Schultz M., Abdel-Mageed A.B., Agrawal K.C. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp. Biol. Med. (Maywood) 2010, 235:751-760.
79. Zubair H., Khan H.Y., Sohail A., Azim S., Ullah M.F., Ahmad A., Sarkar F.H., Hadi S.M. Redox cycling of endogenous copper by thymoquinone leads to ROS-mediated DNA breakage and consequent cell death: putative anticancer mechanism of antioxidants. Cell Death Dis. 2013, 4:e660.
80. Hussain A.R., Ahmed M., Ahmed S., Manogaran P., Platanias L.C., Alvi S.N., Al-Kuraya K.S., Uddin S. Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. Free Radic. Biol. Med. 2011, 50:978-987.
81. Rooney S., Ryan M.F. Modes of action of alpha-hederin and thymoquinone, active constituents of Nigella sativa, against HEp-2 cancer cells. Anticancer Res. 2005, 25:4255-4259.
82. Hussain A.R., Uddin S., Ahmed M., Al-Dayel F., Bavi P.P., Al-Kuraya K.S. Phosphorylated IkappaBalpha predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. PLoS ONE 2013, 8:e60540.
83. El-Najjar N., Chatila M., Moukadem H., Vuorela H., Ocker M., Gandesiri M., Schneider-Stock R., Gali-Muhtasib H. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 2010, 15:183-195.
84. Ulasli S.S., Celik S., Gunay E., Ozdemir M., Hazman O., Ozyurek A., Koyuncu T., Unlu M. Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 non-small cell lung cancer cells exposed to benzo(a)pyrene. Asian Pac. J. Cancer Prev. 2013, 14:6159-6164.
85. Woo C.C., Loo S.Y., Gee V., Yap C.W., Sethi G., Kumar A.P., Tan K.H. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway. Biochem. Pharmacol. 2011, 82:464-475.
86. El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Wani A.A. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int. J. Cancer 2005, 117:409-417.
87. Salim L.Z., Mohan S., Othman R., Abdelwahab S.I., Kamalidehghan B., Sheikh B.Y., Ibrahim M.Y. Thymoquinone induces mitochondria-mediated apoptosis in acute lymphoblastic leukaemia in vitro. Molecules 2013, 18:11219-11240.
88. Das S., Dey K.K., Dey G., Pal I., Majumder A., MaitiChoudhury S., kundu S.C., Mandal M. Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS ONE 2012, 7:e46641.
89. Sakalar C., Yuruk M., Kaya T., Aytekin M., Kuk S., Canatan H. Pronounced transcriptional regulation of apoptotic and TNF-NF-kappa-B signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells. Mol. Cell. Biochem. 2013, 383:243-251.
90. Badr G., Lefevre E.A., Mohany M. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS ONE 2011, 6:e23741.
91. Racoma I.O., Meisen W.H., Wang Q.E., Kaur B., Wani A.A. Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS ONE 2013, 8:e72882.
92. Gali-Muhtasib H., Kuester D., Mawrin C., Bajbouj K., Diestel A., Ocker M., Habold C., Foltzer-Jourdainne C., Schoenfeld P., Peters B., Diab-Assaf M., Pommrich U., Itani W., Lippert H., Roessner A., Schneider-Stock R. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res. 2008, 68:5609-5618.
93. Cecarini V., Quassinti L., Di Blasio A., Bonfili L., Bramucci M., Lupidi G., Cuccioloni M., Mozzicafreddo M., Angeletti M., Eleuteri A.M. Effects of thymoquinone on isolated and cellular proteasomes. FEBS J. 2010, 277:2128-2141.
94. Alhosin M., Abusnina A., Achour M., Sharif T., Muller C., Peluso J., Chataigneau T., Lugnier C., Schini-Kerth V.B., Bronner C., Fuhrmann G. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem. Pharmacol. 2010, 79:1251-1260.
95. Abusnina A., Alhosin M., Keravis T., Muller C.D., Fuhrmann G., Bronner C., Lugnier C. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell. Signal. 2011, 23:152-160.
96. Acharya B.R., Chatterjee A., Ganguli A., Bhattacharya S., Chakrabarti G. Thymoquinone inhibits microtubule polymerization by tubulin binding and causes mitotic arrest following apoptosis in A549 cells. Biochimie 2014, 97:78-91.
97. Alhosin M., Ibrahim A., Boukhari A., Sharif T., Gies J.P., Auger C., Schini-Kerth V.B. Anti-neoplastic agent thymoquinone induces degradation of alpha and beta tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest. New Drugs 2012, 30:1813-1819.
98. Gurung R.L., Lim S.N., Khaw A.K., Soon J.F., Shenoy K., Mohamed Ali S., Jayapal M., Sethu S., Baskar R., Hande M.P. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS ONE 2010, 5:e12124.
99. Peng L., Liu A., Shen Y., Xu H.Z., Yang S.Z., Ying X.Z., Liao W., Liu H.X., Lin Z.Q., Chen Q.Y., Cheng S.W., Shen W.D. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-kappaB pathway. Oncol. Rep. 2013, 29:571-578.
100. Rajput S., Kumar B.N., Sarkar S., Das S., Azab B., Santhekadur P.K., Das S.K., Emdad L., Sarkar D., Fisher P.B., Mandal M. Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS ONE 2013, 8:e61342.
101. Torres M.P., Ponnusamy M.P., Chakraborty S., Smith L.M., Das S., Arafat H.A., Batra S.K. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer Ther. 2010, 9:1419-1431.
102. Ahmad I., Muneer K.M., Tamimi I.A., Chang M.E., Ata M.O., Yusuf N. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol. Appl. Pharmacol. 2013, 270:70-76.
103. Kolli-Bouhafs K., Boukhari A., Abusnina A., Velot E., Gies J.P., Lugnier C., Ronde P. Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation. Invest. New Drugs 2012, 30:2121-2131.
104. Siveen K.S., Mustafa N., Li F., Kannaiyan R., Ahn K.S., Kumar A.P., Chng W.J., Sethi G. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-kappaB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget 2014, 5:634-648.
105. Banerjee S., Kaseb A.O., Wang Z., Kong D., Mohammad M., Padhye S., Sarkar F.H., Mohammad R.M. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009, 69:5575-5583.
106. Nessa M.U., Beale P., Chan C., Yu J.Q., Huq F. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res. 2011, 31:3789-3797.
107. Arafa el S.A., Zhu Q., Shah Z.I., Wani G., Barakat B.M., Racoma I., El-Mahdy M.A., Wani A.A. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat. Res. 2011, 706:28-35.
108. Abdelfadil E., Cheng Y.H., Bau D.T., Ting W.J., Chen L.M., Hsu H.H., Lin Y.M., Chen R.J., Tsai F.J., Tsai C.H., Huang C.Y. Thymoquinone induces apoptosis in oral cancer cells through p38beta inhibition. Am. J. Chin. Med. 2013, 41:683-696.
109. Zhang D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 2006, 38:769-789.
110. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
111. Surh Y.J., Kundu J.K., Na H.K., Lee J.S. Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J. Nutr. 2005, 135:2993S-3001S.
112. Sethi G., Ahn K.S., Aggarwal B.B. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol. Cancer Res. 2008, 6:1059-1070.
113. Sayed A.A., Morcos M. Thymoquinone decreases AGE-induced NF-kappaB activation in proximal tubular epithelial cells. Phytother. Res. 2007, 21:898-899.
114. Li F., Rajendran P., Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br. J. Pharmacol. 2010, 161:541-554.
115. Badr G., Mohany M., Abu-Tarboush F. Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis. 2011, 10:236.
116. Badary O., Al-Shabanah O., Nagi M., Al-Bekairi A., Elmazar M. Acute and subchronic toxicity of thymoquinone in mice. Drug Dev. Res. 1998, 44:56-61.
117. Tubesha Z., Imam M.U., Mahmud R., Ismail M. Study on the potential toxicity of a thymoquinone-rich fraction nanoemulsion in Sprague Dawley rats. Molecules 2013, 18:7460-7472.
118. Akhondian J., Kianifar H., Raoofziaee M., Moayedpour A., Toosi M.B., Khajedaluee M. The effect of thymoquinone on intractable pediatric seizures (pilot study). Epilepsy Res. 2011, 93:39-43.
119. Banerjee S., Azmi A.S., Padhye S., Singh M.W., Baruah J.B., Philip P.A., Sarkar F.H., Mohammad R.M. Structure-activity studies on therapeutic potential of thymoquinone analogs in pancreatic cancer. Pharm. Res. 2010, 27:1146-1158.
120. Wirries A., Breyer S., Quint K., Schobert R., Ocker M. Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells. Exp. Ther. Med. 2010, 1:369-375.
121. Breyer S., Effenberger K., Schobert R. Effects of thymoquinone-fatty acid conjugates on cancer cells. ChemMedChem 2009, 4:761-768.
122. Ravindran J., Nair H.B., Sung B., Prasad S., Tekmal R.R., Aggarwal B.B. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem. Pharmacol. 2010, 79:1640-1647.
123. Ganea G.M., Fakayode S.O., Losso J.N., van Nostrum C.F., Sabliov C.M., Warner I.M. Delivery of phytochemical thymoquinone using molecular micelle modified poly(d, l lactide-co-glycolide) (PLGA) nanoparticles. Nanotechnology 2010, 21:285104.